Immune tolerance of allogeneic haematopoietic cell transplantation supports donor epidermal grafting of recessive dystrophic epidermolysis bullosa chronic wounds.

ABSTRACT:

Background

Chronic wounds, a common morbidity in recessive dystrophic epidermolysis bullosa (RDEB), lack definitive therapies.

Objectives

To assess allogeneic epidermal skin grafts in terms of wound healing and durability over time.

Methods

In a prospective, open-label clinical trial for postallogeneic haematopoietic cell transplantation (post-alloHCT) patients with RDEB, up to nine chronic wounds per patient were grafted over 1 year. Epidermal grafts measuring 5 cm² were obtained from related alloHCT donors in the outpatient setting using the CELLUTOME^TM Epidermal Harvesting System. Wounds were photographed and symptom inventories completed at baseline and 6, 12 and 52 weeks after grafting. The trial was registered at ClinicalTrials.gov (NCT0267

SUBMITTER: Ebens CL 

PROVIDER: S-EPMC7914301 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature